EI
RCUS icon

EAM Investors’s Arcus Biosciences RCUS Stock Holding History

EAM Investors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-76,163
Closed -$3.08M – 367
2021
Q4 		$3.08M Buy
+76,163
New +$2.95M 0.51% 50
2020
Q3 		– Sell
-65,606
Closed -$1.62M – 343
2020
Q2 		$1.62M Buy
+65,606
New +$1.77M 0.36% 135

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

EAM Investors's RCUS Position: Q1 2022 in Review

EAM Investors sold out of Arcus Biosciences (RCUS) in Q1 2022, closing a stake of 76,163 shares — an estimated $3.08M sold.

EAM Investors first reported a position in RCUS in Q2 2020 and held it in 2 quarters. The position peaked at $3.08M in Q4 2021. 157 funds tracked by Wall St. Rank hold RCUS as of Q1 2022.

  • EAM Investors reported no remaining Arcus Biosciences position as of Q1 2022 after selling out during the quarter.
  • EAM Investors sold 76,163 Arcus Biosciences shares in Q1 2022, an estimated $3.08M.
  • EAM Investors first reported a position in Arcus Biosciences in Q2 2020 and held it in 2 quarters.
  • EAM Investors's Arcus Biosciences position peaked at $3.08M in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2022.

Based on EAM Investors's 13F filing for Q1 2022, filed 13 May 2022.